↓ Skip to main content

Cochrane Database of Systematic Reviews

Hyperbaric oxygen therapy for multiple sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, January 2004
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

policy
1 policy source
twitter
16 X users
wikipedia
17 Wikipedia pages

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
105 Mendeley
Title
Hyperbaric oxygen therapy for multiple sclerosis
Published in
Cochrane database of systematic reviews, January 2004
DOI 10.1002/14651858.cd003057.pub2
Pubmed ID
Authors

Michael H Bennett, Robert Heard

Abstract

Multiple Sclerosis (MS) is a chronic, recurrent and progressive illness with no cure. On the basis of speculative pathophysiology, it has been suggested that Hyperbaric Oxygen Therapy (HBOT) may slow or reverse the progress of the disease.

X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Unknown 104 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 15 14%
Student > Bachelor 14 13%
Student > Ph. D. Student 13 12%
Researcher 9 9%
Other 4 4%
Other 11 10%
Unknown 39 37%
Readers by discipline Count As %
Medicine and Dentistry 26 25%
Neuroscience 7 7%
Nursing and Health Professions 5 5%
Biochemistry, Genetics and Molecular Biology 4 4%
Psychology 4 4%
Other 17 16%
Unknown 42 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2023.
All research outputs
#1,945,869
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#4,162
of 11,499 outputs
Outputs of similar age
#4,087
of 147,690 outputs
Outputs of similar age from Cochrane database of systematic reviews
#12
of 52 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 147,690 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.